Oxford Nanopore Technologies Limited

Glaxo Group Limited

Mark Bruce

Andrew John Heron

Lakmal Nishantha Jayasinghe

Elizabeth Jayne Wallace

Rebecca Victoria Bowen

Szabolcs Soeroes

James White

James Anthony Clarke

Luke McNeill

Ruth Moysey

Domenico Caprotti

Neil Roger Wood

Christopher Peter Youd

Ramiz Iqbal Nathani

John Milton

Clive Gavin Brown

David Alves

Darrell Baker

Marian Thomas

Stephen Robert Young

Richard George Hambley

Pratik Raj Singh

Jonathan Bankes Pugh

Joseph Hargreaves Lloyd

Brian Noga

Glenn Crater

Patrick Wire

Luke Mcneill

Christopher James Wright

David Jackson Stoddart

Richard Muscat

Paul Richard Moody

Mihaela Misca

Anthony Clarke

Jessica Mary May Johnson

Antonino Puglisi

Jessica Mary May Knott

David Antoni Alves

Jayne Wallace

Lakmal Jayasinghe

Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, compositions thereof, and methods of using them are provided.

Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using the mutant forms of lysenin.

Mutant pore

The invention relates to a new method of characterising a target polynucleotide. The method uses a pore and a Dda helicase. The helicase controls the movement of the target polynucleotide through the pore. The invention also relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

Modified helicases

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.

Mutant lysenin pores

The invention relates to modified helicases with reduced unbinding from polynucleotides. The helicases can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

The invention relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

Modified enzymes

Methods of characterizing an analyte using a detector such as a nanopore and an enzyme are provided. One aspect features methods for characterizing a double-stranded polynucleotide using a detector, e.g., without using a hairpin connecting a template and a complement of the double-stranded polynucleotide. Another aspect features methods for characterizing an analyte using a tag-modified nanopore with increased sensitivity and/or higher throughput. Compositions and systems including, e.g., adaptors for attachment to double-stranded polynucleotides and tag-modified nanopores, which can be used in the methods are also provided.

Method of characterizing a polynucleotide

The invention relates to improving the movement of a target polynucleotide with respect to a transmembrane pore when the movement is controlled by a polynucleotide binding protein. The invention also relates to improved transmembrane pores and polynucleotide binding proteins.

Method of improving the movement of a target polynucleotide with respect to a transmembrane pore

Methods of characterizing an analyte using a nanopore. One aspect features methods for characterizing a double-stranded polynucleotide using a nanopore, e.g., without using a hairpin connecting a template and a complement of the double-stranded polynucleotide. Another aspect features methods for characterizing an analyte using a tag-modified nanopore with increased sensitivity and/or higher throughput. Compositions and systems including, e.g., adaptors for attachment to double-stranded polynucleotides and tag-modified nanopores, which can be used in the methods are also provided.

Methods and systems for characterizing analytes using nanopores

Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.

Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol

Growing community of inventors

Oxford, United Kingdom

Mark Bruce